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ABSTRACT
Objective: To determine if urinary lipoarabinomannan
(LAM) may serve as a biomarker to monitor
antituberculosis (TB) therapy response, and whether
LAM results before and after treatment are predictive of
patient outcomes.
Design: Prospective cohort.
Setting: Outpatient referral clinic and tertiary hospital
in South Africa.
Participants: Adults (≥18 years) with ≥2 TB-related
symptoms (cough, fever, weight loss, night sweats) for
≥2 weeks being initiated on anti-TB therapy.
Interventions: On enrolment, we obtained urine and
nebulised sputum specimens, offered HIV testing and
started participants on anti-TB therapy for ≥6 months.
We collected urine samples after the 2-month intensive
treatment phase and at the completion of anti-TB
therapy. Positive LAM results were graded from 1 (low)
to 5 (high). Participants were followed for >3 years.
Outcome measures: The primary outcome was
change in urine LAM results during anti-TB therapy.
The secondary outcome was all-cause mortality.
Results: Among 90 participants, 57 (63%) had
culture-confirmed pulmonary TB. Among the 88
participants tested, 82 (93%) were HIV-infected with
median CD4 168/mm3 (IQR 89–256/mm3). During
anti-TB therapy, the percentage of LAM-positive
participants decreased from baseline to 2 months
(32% to 16%), and from baseline to 6-months (32%
to 10%) (p values <0.005). In multivariate longitudinal
analyses, urine LAM positivity and grade decreased
among those with culture-confirmed pulmonary TB
(p<0.0001), and had no change in sputum culture-
negative participants. At the 2-month visit, participants
with positive laboratory-based LAM or rapid LAM with
≥2+ grade had a significantly greater risk of mortality.
In analyses adjusted for age, sex, baseline Karnofsky
score and HIV status, participants with a rapid LAM
≥2+ grade after 2 months of anti-TB therapy had a
5.6-fold (95% CI 1.2 to 25.2) greater risk of mortality.
Conclusions: Rapid urine LAM testing may be a
valuable tool to monitor anti-TB therapy response and
to assess prognosis of patients being treated for
pulmonary TB in HIV-endemic regions.
INTRODUCTION
In 2012, approximately 1.3 million people
died from Mycobacterium tuberculosis (TB)
worldwide, many of whom were coinfected
with HIV.1 In South Africa, nearly two-thirds
of people diagnosed with active TB are also
coinfected with HIV.2 The HIV/AIDS epi-
demic has spurred a resurgence of TB, and
new diagnostic tools are needed for diagnos-
ing TB, monitoring a patient’s response to
treatment and evaluating the efficacy of
various TB regimens.2–4 Reducing the global
burden of TB may rely on improved diagnos-
tics for initial case identification and monitor-
ing response to anti-TB therapy, particularly
among HIV-infected individuals.5 6
The estimated rate of treatment failure or
disease relapse among patients receiving a
standard 6-month regimen for drug-
susceptible TB is 10%.5 A sputum specimen
after the initial 2-month intensive treatment
phase has been previously recommended as
a prognostic marker of successful treatment.6
However, a recent meta-analysis found
sputum smear microscopy for acid-fast bacilli
(AFB) and mycobacterial culture status after
Strengths and limitations of this study
▪ Stored urine samples were retrieved from a freezer
for rapid lipoarabinomannan (LAM) testing.
▪ The sample size was not powered to detect dif-
ferences in measures of clinical improvement,
which had not reached statistical significance.
▪ An induced sputum sample for culture is an
imperfect gold standard test for pulmonary
tuberculosis (TB), which may have caused mis-
classification of urine LAM tests.
▪ The primary strengths of our study were the lon-
gitudinal assessment of urine LAM during
anti-TB therapy and the long follow-up period to
assess patient outcomes.
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the intensive phase of therapy to be poor predictors of
treatment failure or disease relapse.7 Consequently, the
WHO recently downgraded sputum smear microscopy
for AFB at the completion of the 2-month intensive
phase of treatment to a conditional recommendation.8
A rapid clinic-based test for a pathogen biomarker
might serve as a diagnostic tool for monitoring anti-TB
therapy response and assessing a patient’s prognosis.4 6
The Xpert MTB/RIF assay is more sensitive than
sputum smear microscopy,9 but the assay’s high cost and
placement in centralised reference laboratories has
reduced its potential clinical impact.10 Furthermore,
since the Xpert assay is unable to discriminate between
live and dead bacteria, it is not recommended for moni-
toring a patient’s response to anti-TB therapy.11
Lipoarabinomannan (LAM) is a prominent glycolipid in
the cell wall of TB and may serve as a useful pathogen
biomarker to assess response to anti-TB therapy, particu-
larly among HIV-infected adults.12 Therefore, we sought
to determine if urinary LAM may serve as a biomarker
to monitor anti-TB therapy response, and whether a
positive LAM result after the 2-month intensive phase of
therapy predicts mortality in an HIV-endemic region.
METHODS
Study design and participant selection
We conducted a prospective cohort study of patients
being initiated on anti-TB therapy at the Infectious
Diseases referral clinic of King Edward VIII Hospital in
Durban, South Africa from November 2008 to
December 2010. The parent study was designed to assess
the diagnostic value of an overnight oesophageal string,
and has been previously reported.13 In brief, eligible
participants were ≥18 years old, had a high probability
of pulmonary TB based on the presence of at least two
of four TB-related symptoms (cough, fever, weight loss,
night sweats)14 for at least 2 weeks, and were either
unable to produce a respiratory sputum sample or had
at least two negative expectorated sputum samples for
AFB by smear microscopy. We excluded patients who
had a Karnofsky performance score <50, had taken
anti-TB medications within the past 3 months, or had
respiratory distress, chronic obstructive pulmonary
disease or cardiac failure. We excluded any patients who
improved after a short course of empiric amoxicillin,
which was common practice for sputa smear-negative TB
suspects in South Africa. All participants provided
written informed consent.
Study procedures
On enrolment, we obtained a detailed social and
medical history of participants who were admitted to the
hospital for observation. For all participants, we per-
formed early-morning sputum induction with 5% hyper-
tonic saline using an ultrasonic nebuliser and obtained a
urine sample. Respiratory samples were tested by smear
microscopy for AFB and mycobacterial culture.
All participants were then started on a standard, weight-
based, fixed-dose combination of isoniazid, rifampin,
ethambutol and pyrazinamide. Participants returned to
the clinic each month, where nurses measured partici-
pants’ weight and recorded the number of TB-related
symptoms (cough, fever, weight loss, night sweats). After
each clinical encounter, a physician recorded whether,
in their judgement, the participant was clinically improv-
ing or not. We collected additional urine samples at the
end of the intensive treatment phase (2-month visit)
and at the completion of anti-TB therapy (6-month
visit). Sputum samples were obtained at the 2-month
and 6-month visits among participants with a productive
cough or clinical deterioration, which followed standard-
of-care practices for TB treatment follow-up in South
Africa. Participants who had improved after 2 months of
standard anti-TB therapy were switched to isoniazid and
rifampin for four additional months of anti-TB therapy.
All participants were referred for initiation of antiretro-
viral therapy in accordance with South African
guidelines.15
Laboratory testing
Direct microscopy for AFB was performed with both
Ziehl-Nielsen and auramine stains. Mycobacterial culture
was performed with liquid culture media (BACTEC
MGIT BD, Sparks, MD, USA) and solid culture media.
Positive cultures were identified as M. tuberculosis using
the niacin test. All laboratory investigations were per-
formed at accredited laboratories by technicians regis-
tered with the Health Professions Council of South
Africa, and laboratory technicians evaluating specimens
for positive mycobacterial smear and/or culture did not
have access to LAM results.
Laboratory-based urine LAM testing was performed
using an ELISA test, measured with a 340–750 nm spec-
tral range microplate reader (Bio Rad Inc., Hercules,
USA), and conducted by the same operator. Rapid LAM
testing was performed on stored, frozen urine samples
using the Determine TB LAM test (Alere Inc., Waltham,
USA) in accordance with the manufacturer’s specifica-
tions.16 In brief, frozen urine specimens were brought to
room temperature and centrifuged at 10 000 g for at
least 5 min prior to testing. Using a sterile pipette, 60 µL
of the clear supernatant of the urine sample was trans-
ferred to the test strip. Two readers (PKD and LG) inde-
pendently interpreted the LAM test results after 25 min.
Positive tests were graded from 1+ (lowest intensity) to
5+ (highest intensity), using the manufacturer’s original
reference guide with five positive categories. During
rapid urine LAM testing, both readers were blind to par-
ticipants’ identification and medical information.
Statistical analyses
Induced sputum culture for M. tuberculosis was the gold-
standard diagnostic test for active pulmonary TB. For
this pilot study, the estimated sample size was calculated
with 30% urine LAM-positive at baseline and a 30%
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decrease in test positivity was observed after 2 months of
therapy. Results were stratified by HIV-infection and
CD4 count. We used Fisher’s exact test and Wilcoxon
rank sum test to compare baseline characteristics
between those rapid urine LAM positive and negative.
We compared the urine LAM test results, both by per-
centage of participants LAM-positive and mean LAM
grade, for follow-up visits against the baseline values
using McNemar’s test for paired binary outcomes and
paired Student’s t tests for continuous outcomes. We
assessed clinical improvement by weight gain, evaluating
resolution of TB-related symptoms, and physician assess-
ment for clinical improvement independent of LAM
results, in the month following urine LAM testing. We
used multivariate repeated measure logistic and linear
regression models for dichotomous and continuous
measures stratified by sputum culture status. The urine
LAM test grade was natural log transformed to approxi-
mate a normal distribution for regression analyses.
Kaplan-Meier curves were used to display survival among
participants by rapid urine LAM status after 2 months of
anti-TB therapy; curves were compared using a log-rank
test. We used Cox proportional hazard regression to
assess relationships between laboratory-based and rapid
urine LAM tests at baseline, 2 and 6 months of anti-TB
therapy. Mortality from any cause was determined
through the South Africa Department of Home Affairs
national death registry. All regression models were
adjusted for age and gender. Multivariate Cox propor-
tional hazard regressions were also adjusted for baseline
Karnofsky performance score and HIV status. Since CD4
count was not measured for all participants, we con-
ducted separate multivariate Cox proportional hazard
regressions with additional adjustment for baseline CD4
count. We provided 95% CIs, used two-tailed α<0.05 as
significant, and conducted analyses using SAS (V.9.2).
RESULTS
Among the 90 participants, the mean age was 36.9 years
(SD±9.3 years) and 44 of the participants (49%) were
woman (table 1). At enrolment, the mean body mass
index was 21.8 kg/m2 (±3.5 kg/m2), 37 participants
(41%) had a Karnofsky score ≤90 and 75 (83%) partici-
pants had 4 of 4 TB-related symptoms. Of the 88 partici-
pants tested for HIV, 82 (93%) were HIV-infected with a
median CD4 cell count of 168/mm3 (IQR 89–256/
mm3). Within this cohort, those eligible and started on
antiretroviral therapy were started at a mean duration of
138.2 (SD±92.1) days after initiation of anti-TB therapy.
Induced sputum samples from 14 participants (16%)
were AFB smear-positive, and 57 (63%) participants had
sputum culture-confirmed pulmonary TB.
In total, we tested 213 urine samples by both the
laboratory-based and rapid LAM antigen assays, and we
have previously reported the diagnostic accuracy of
these tests.17 In brief, 20 (22%) and 29 (32%) partici-
pants had a positive baseline laboratory-based test and
rapid urinary LAM test, respectively. The diagnostic sen-
sitivity and specificity of the laboratory-based urine LAM
test were 32% (95% CI 20% to 45%) and 94% (95% CI
79% to 99%). The diagnostic sensitivity and specificity of
Table 1 Baseline cohort characteristics by rapid urine LAM test result (N=90)
LAM negative (N=61) LAM positive (N=29) p Value
Demographics
Mean age, years (SD) 37.6 (10.2) 35.4 (7.3) 0.25
Female (%) 28 (45.9) 16 (55.2) 0.50
Clinical
Mean weight, kilograms (SD) 59.8 (10.1) 58.6 (11.4) 0.69
Mean BMI, kilograms/meter2 (SD) 21.9 (3.4) 21.5 (3.8) 0.68
Karnofsky performance score 0.0008
100 (%) 43 (70.5) 10 (34.5)
90 (%) 13 (21.3) 6 (20.7)
≤80 (%) 4 (6.6) 12 (41.4)
Number of tuberculosis symptoms* 0.17
4 (%) 48 (78.7) 27 (93.1)
3 (%) 8 (13.1) 2 (6.9)
2 (%) 5 (8.2) 0 (0)
HIV testing (N=88)
HIV-infected (%) 54 (91.5) 28 (96.6) 0.66
Median CD4 count/mm3 among HIV+ (IQR) 198 (102–270) 106 (44–218) 0.03
Tuberculosis testing by sputum induction
AFB Smear Microscopy positive (%) 8 (13.1) 6 (20.7) 0.39
Culture positive (%) 33 (54.1) 24 (82.8) 0.004
Data are proportion of participants (%), unless otherwise indicated.
*Includes cough, fever, night sweats, weight loss.
AFB, acid-fast bacilli; BMI, body mass index (calculated as the weight in kilograms divided by the square of the height in metres);
LAM, lipoarabinomannan.
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the rapid urine LAM test were 42% (95% CI 29% to
56%) and 85% (95% CI 68% to 95%). Participants with
a positive rapid urine LAM result at baseline had signifi-
cantly lower Karnofsky performance scores and a signifi-
cantly lower median CD4 count, compared to rapid
urine LAM-negative participants (table 1).
Participants were followed for a median of 49 months
(IQR 45.8–50.9 months) from the date of enrolment. All
90 participants who returned for follow-up visits pro-
vided a urine sample for LAM testing. Following South
Africa’s standard-of-care practices, 8 of 73 (11%) and 11
of 50 (22%) participants provided an expectorated
sputum sample at the 2-month and 6-month follow-up
visits, respectively. During the 3-year follow-up period, 25
(28%) participants died; 5 (6%) died while still receiv-
ing anti-TB therapy.
Urine LAM to monitor response to anti-TB therapy
During the course of anti-TB therapy, the overall per-
centage of rapid urine LAM-positive participants
decreased from baseline to 2 months (32% to 16%),
and from baseline to 6 months (32% to 10%) (table 2).
Eighteen of the 29 (62%) LAM-positive participants at
baseline became LAM-negative at the 2-month follow-up
visit (p=0.0009). One person, who was LAM-negative
and sputum culture-negative at baseline, became LAM-
positive at the 2-month visit. After 6 months of anti-TB
therapy, only five participants were LAM-positive. This
included two participants who became LAM-positive for
the first time at the 6-month visit. Therefore, 26 of the
29 (90%) LAM-positive participants at baseline became
LAM-negative after 6 months of anti-TB therapy
(p=0.004). The overall mean urine LAM test grade
decreased from 0.7 (±1.3) at baseline to 0.5 (±1.3) at
2 months to 0.2 (±0.7) at the 6-month visit (both
p<0.01). Similar results occurred among HIV-infected
participants, and when stratified by CD4 above/below
100 cell/mm3.
Among LAM-positive participants at baseline, the mean
urine LAM grade decreased from 2.2 (±1.5) at baseline
to 1.3 (±1.9) at 2 months to 0.4 (±1.2) at the 6-month visit
(figure 1A). Within our cohort, only one LAM-positive
participant at baseline had an increase in urine LAM
grade during the study period (1+ to 3+ at the 2-month
visit); this person died during the 6-month study period.
Among LAM-negative participants at baseline, there was
no appreciable change in LAM score during 6 months of
anti-TB therapy. However, one participant had a 1+ grade
at the 2-month visit, and two participants had a 1+ grade
at the 6-month visit. In multivariate longitudinal regres-
sion models, rapid urine LAM test positivity and test
grade decreased among LAM-positive participants at
baseline (both p=0.0001), and had no significant change
among LAM-negative participants at baseline, during
6 months of anti-TB therapy.
Urine LAM positivity and grade decreased among
those with culture-confirmed pulmonary TB during the
course of anti-TB therapy (figure 1B). Among TB
culture-positive participants at baseline, the proportion
of those who were LAM-positive decreased from 27% at
baseline to 14% at 2 months to 6% at the 6-month
follow-up visit. Among those who were TB culture-
positive, the mean urine LAM grade decreased from 1.0
(±0.4) at baseline to 0.5 (±0.4) at 2 months to 0.2 (±0.1)
at the 6-month visit (figure 1B). In multivariate longitu-
dinal regression models, culture-positive participants
had a significant decrease in urine LAM test positivity
and grade (both p<0.0001), while there was no signifi-
cant change in urine LAM test positivity or grade among
culture-negative participants.
We assessed the correlation between changes in the
urine LAM result and clinical signs of response to treat-
ment, including weight gain, resolution of TB-related















Rapid urine LAM positive N (%) N (%) N (%)
All participants 29 (32.2) 12 (16.4)* 0.0009 5 (10.0)† 0.004
HIV+ 28 (34.1) 12 (17.6) 0.002 5 (10.6) 0.007
HIV+ and CD4 ≥100/mm3 14 (25.5) 4 (8.2) 0.01 3 (8.6) 0.11
HIV+ and CD4 <100/mm3 14 (51.9) 8 (42.1) 0.25 2 (16.7) 0.06
Rapid urine LAM grade Mean±SD Mean±SD Mean±SD
All participants 0.7±1.3 0.5±1.2 0.005 0.2±0.7 0.006
HIV+ 0.8±1.4 0.5±1.3 0.007 0.2±0.8 0.008
HIV+ and CD4 ≥100/mm3 0.5±1.0 0.2±0.8 0.007 0.1±0.3 0.04
HIV+ and CD4 <100/mm3 1.3±1.8 1.3±1.9‡ 0.31 0.5±1.4 0.08
*1 culture-negative participant with negative baseline rapid urinary LAM became positive at the 2-month follow-up visit.
†2 culture-positive participants with negative baseline rapid urinary LAM became positive at the 6-month follow-up visit.
‡1 culture-positive participant with 1+ grade at baseline rapid urinary LAM became 3+ at the 2 month follow-up visit; this participant died
during the study.
LAM, lipoarabinomannan; TB, tuberculosis.
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symptoms and physician assessment for clinical improve-
ment (table 3). Over the month following each clinical
visit, LAM-negative participants had more average weight
gain, better resolution of TB-related symptoms and a
higher perception of clinical improvement by the phys-
ician, as compared to LAM-positive participants.
However, these markers of clinical improvement did not
reach statistical significance in this pilot study.
Urine LAM as a predictor of mortality
Participants with a positive laboratory-based or rapid
LAM test result after the 2-month intensive treatment
phase had a greater risk of mortality during the 3-year
follow-up period (table 4). Participants with a strongly
positive rapid urine LAM result (≥2+ grade) at the
2-month visit had an earlier median time to death (35.9
months), compared to participants with a weakly positive
(1+ grade) or negative rapid urine LAM test
(42.0 months) (p=0.02; figure 2). In univariate analyses,
a positive laboratory-based LAM test or a rapid LAM
grade ≥2+ at the 2-month visit was each significantly
associated with all-cause mortality. In multivariate ana-
lyses adjusted for age, gender, Karnofsky performance
score and HIV status, participants with a positive lab-
based LAM test or a rapid LAM grade ≥2+ had a 4.13
(95% CI 0.88 to 19.4) and 5.58 (95% CI 1.24 to 25.2)
hazard risk of death from any cause. Adjusting for the
baseline CD4 count in the multivariate proportional
hazard regression for the rapid LAM grade ≥2+ led to
similar significant results (HR=5.01; 95% CI 1.05 to
23.9). Participants with a positive rapid LAM test at the
6-month visit had an adjusted hazard risk of 42.1 (95%
CI 1.87 to 952) for mortality during the follow-up
period. The HR remained significant when adjusting
the same multivariate regression analysis for baseline
CD4 count (HR=55.3; 95% CI 2.06 to 1484). The lab-
based or rapid LAM test results at baseline were not sig-
nificantly associated with mortality during the 3-year
follow-up period.
DISCUSSION
In our setting, urinary LAM decreased during the
6 months of anti-TB therapy among TB culture-positive
patients, and participants who were LAM-positive after
completing the intensive phase of anti-TB therapy had a
greater risk of mortality. The rapid urine LAM test
returned results within 25 min and did not require add-
itional reagents, machinery or highly trained laboratory
microscopists. The results from this pilot study suggest
that the rapid urine LAM assay may be a convenient,
accessible tool to monitor anti-TB therapy response and
to assess prognosis of patients being treated for pulmon-
ary TB in HIV-endemic regions.
The diagnostic accuracy of the rapid LAM test has
been reported in other hospital-based studies.18–22 In a
retrospective study of hospitalised HIV-infected TB sus-
pects in Cape Town, the rapid LAM test had a sensitivity
of 66% and specificity of 66%, which increased to 90%
when using a non-TB control group.18 Among hospita-
lised HIV-infected suspects in South Africa and Uganda,
the rapid urine LAM test had a diagnostic sensitivity and
specificity of 62–63% and 78–88%, respectively.19 20
Although these cohorts have generally included sicker
hospitalised patients, the reported diagnostic test
characteristics have been similar. Our study is unique in
assessing the urinary LAM as a potential biomarker to
monitor response to anti-TB therapy and assess progno-
sis of patients being treated for pulmonary TB. To the
best of our knowledge, this is the first longitudinal study
to evaluate the rapid urine LAM test in this manner.
Figure 1 (A) Rapid urine LAM grade during 6 months of
anti-TB therapy for urine LAM-positive and LAM-negative
participants at baseline. Error bars represent 95% CIs. We
used natural-log transformed values of urine LAM grade to
assess significant decrease for longitudinal regression
models. (B) Rapid urine LAM grade during 6 months of
anti-TB therapy for sputum culture-positive and
culture-negative for pulmonary TB participants at baseline.
Error bars represent 95% CIs. We used natural-log
transformed values of urine LAM grade to assess significant
decrease for longitudinal regression models (LAM,
lipoarabinomannan; TB, tuberculosis).
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Our findings suggest that urinary LAM may be a valu-
able pathogen biomarker to monitor response to
anti-TB therapy among patients being treated for pul-
monary TB. Sputum culture has been used for treat-
ment monitoring and as a surrogate measure for drug
approval,23 but is a poor predictor of treatment failure
or disease relapse.7 The early stoppage of a study of
shorter treatment duration among patients who con-
verted sputum culture after 2 months of therapy high-
lighted the limited role of sputum monitoring.24 Other
studies have measured the rate of decline of viable TB
in sputum during therapy as colony counts on agar, time
to positivity in liquid culture or levels of TB antigen 85
and 85B RNA in sputum, but these tests are currently
not suited to rapid clinic-based testing.25–28 In our study,
few participants could provide an expectorated sputum
sample at the 2-month and 6-month visits, but nearly all
participants were capable of providing a urine sample.
Measuring a pathogen biomarker in urine with a
point-of-care lateral flow assay has many additional
advantages over conventional sputum microscopy and
culture, including reduced risk of transmission to health-
care workers.
These findings are biologically plausible, since patients
with LAM being excreted in urine are likely to have a
high bacillary load of TB.29 In our cohort, participants
who were urine LAM positive at baseline had lower
Karnofsky scores, more TB-related symptoms and a













month (%) p Value
Baseline visit
Rapid LAM negative 56 0.8±2.7 0.6±0.9 96.4
Rapid LAM positive 29 −0.1±3.0 0.17 0.9±1.2 0.17 89.7 0.33
2-month follow-up
Rapid LAM negative 60 0.7±2.4 0.6±1.0 90.0
Rapid LAM positive 12 −0.5±3.6 0.16 0.8±1.1 0.41 83.3 0.61
6-month follow-up*
Rapid LAM negative 45 1.0±1.8 0.2±0.5 100
Rapid LAM positive 5 0.4±0.9 0.52 0.4±0.9 0.41 100 1.00
*Data represent change from the 5-month to the 6-month follow-up visits.
LAM, lipoarabinomannan; TB, tuberculosis.






HR (95% CI) p Value
Multivariate
HR* (95% CI) p Value
Baseline visit
Laboratory-based LAM negative 19/70 (27.1) 1.00 (reference) – 1.00 (reference) –
Laboratory-based LAM positive 6/20 (30.0) 1.13 (0.45–2.83) 0.79 1.19 (0.40–3.55) 0.75
Rapid LAM negative 16/61 (31.0) 1.00 (reference) – 1.00 (reference) –
Rapid LAM positive 9/29 (31.0) 1.22 (0.54–2.76) 0.63 1.41 (0.54–3.70) 0.49
Rapid LAM score <2 21/76 (27.6) 1.00 (reference) – 1.00 (reference) –
Rapid LAM score ≥2 4/14 (28.6) 1.04 (0.36–3.04) 0.66 0.99 (0.28–3.58) 0.99
2-month visit
Laboratory-based LAM negative 12/64 (18.8) 1.00 (reference) – 1.00 (reference) –
Labratory-based LAM positive 4/9 (44.4) 3.05 (0.98–9.48) 0.05 4.13 (0.88–19.4) 0.07
Rapid LAM negative 12/61 (19.7) 1.00 (reference) – 1.00 (reference) –
Rapid LAM positive 4/12 (33.3) 2.00 (0.65–6.21) 0.23 1.99 (0.52–7.65) 0.32
Rapid LAM grade <2 12/65 (18.5) 1.00 (reference) – 1.00 (reference) –
Rapid LAM grade ≥2 4/8 (50.0) 3.63 (1.17–11.3) 0.03 5.58 (1.24–25.2) 0.03
6-month visit
Rapid LAM negative 4/45 (8.9) 1.00 (reference) – 1.00 (reference) –
Rapid LAM positive 2/5 (40.0) 5.56 (1.00–30.7) 0.05 42.1 (1.87–952) 0.02
*Models adjusted by age, gender, Karnofsky performance score and HIV status.
Rapid LAM result modelled as negative (grade <1) versus positive (grade ≥1), and grade <2 versus grade ≥2.
LAM, lipoarabinomannan; TB, tuberculosis.
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lower median CD4 count, all consistent with a higher
burden of TB disease. However, decreasing urine LAM
levels may simply represent a change in the balance
between LAM release by dead or dying bacilli and
limited renal excretion. A positive urine LAM after the
intensive phase of anti-TB therapy may prompt further
clinical evaluations, including drug-resistance TB and/
or medication adherence. Since endogenous TB relapse
may be a failure to eradicate metabolically less active
bacilli remote from cavity sources, urine LAM testing
may also be well suited to detect extrapulmonary
bacilli.30
Our study has several strengths and limitations. We
thawed stored urine samples for rapid LAM testing,
which may not give the same results as fresh urine speci-
mens. Since this was a pilot study, the sample size was
not powered to detect differences in the clinical
improvement of participants. An induced sputum
sample for culture is an imperfect gold standard test for
pulmonary TB; the cause of a participant’s death was
not available. Finally, we evaluated urine LAM as an out-
patient diagnostic test among predominantly HIV-
infected TB suspects in a TB-endemic region, and these
results may not be generalisable to other populations or
areas with low TB rates. The primary strengths of our
study were the longitudinal assessment of urine LAM
during anti-TB therapy and the long follow-up period to
assess patient outcomes.
In conclusion, urine LAM testing may be an accessible
method to monitor response to anti-TB therapy among
patients being treated for TB in HIV-endemic, resource-
limited settings. Rapid urine LAM test characteristics
improved among HIV-infected people at risk of mortality
and identified those in need of close observation. Since
urine LAM testing has several appealing properties and
may be used at the clinical point-of-care, a larger clinical
trial is warranted to determine if a persistently positive
urine LAM is associated with drug-resistant TB, poor
medication adherence or absence of a therapeutic
response.
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